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accreta was reported in 1937,1	 the	main	 and	often	only	 approach	
to	management	 was	 a	 cesarean	 hysterectomy.	 This	 approach	 had	
the	advantage	of	reducing	the	immediate	risks	of	major	hemorrhage	
associated	with	accreta	placentation	at	 a	time	when	 there	was	no	
access to blood transfusion.
Over	 the	 last	 two	decades,	 a	variety	of	 conservative	options	 for	









In	 cases	 of	 high	 suspicion	 for	 PAS	 disorders	 during	 cesarean	
delivery,	the	majority	of	members	of	the	Society	for	Maternal-	Fetal	
Medicine	 (SMFM)	 proceed	with	 hysterectomy	 and	 only	 15%–32%	
report	conservative	management.6,7	However,	there	is	considerable	
practice	variation	reported	on	aspects	of	care	around	delivery	and	
hysterectomy	 by	 both	 obstetricians	 and	 maternal-	fetal	 medicine	
specialists.6,8	 There	 is	 also	 wide	 variation	 between	 high-	income	
countries and low- and middle- income countries owing to limited 
or	 no	 access	 to	 specialist	 care	 and	 essential	 additional	 treatment,	
such	as	blood	products	 for	 transfusion.	Hysterectomy	 remains	 the	





nonconservative	 surgery	 (i.e.	 cesarean	hysterectomy)	 for	 the	man-
agement	of	PAS	disorders.
2  | PREPARATION FOR THE  










ing	 coagulopathy,	multisystem	organ	 failure,	 and	death9–20	 (Table	1).	
Surgical	risks	increase	with	the	depth	of	placental	invasion,	with	women	
presenting	 with	 placenta	 percreta	 more	 likely	 to	 require	 additional	
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blood	products,	 have	urologic	 injury,	 and	 require	 intensive	 care	unit	
admission	than	women	with	placenta	creta	(vera	or	adherenta).10,21,22
Accurate prenatal diagnosis, careful planning, and close commu-
nication	 are	 essential,	 including	 the	 creation	 of	 specialized	 surgical	
teams	to	execute	a	safe	care	plan	for	patients	with	PAS	disorders.
2.1 | Multidisciplinary team care











protocol11,15,17,23	 (Table	3).	 Each	 component	 within	 the	 care	 plan	 is	
important.	In	a	Canadian	prospective	chart	review	of	33	patients	within	
a	CoE,	stepwise	increasing	use	of	MDT	components	was	significantly	
associated	with	 a	 reduction	 in	 composite	morbidity,9	which	 demon-
strates	the	additive	value	of	each	component	of	care.	A	sufficient	vol-
ume	of	cases	per	year	to	maintain	the	experience	of	the	MDT	is	crucial.














registry,	 a	 population-	based	 cross-	sectional	 study	 found	 that	 nearly	
half	(49%)	of	the	women	requiring	a	massive	transfusion	present	with	a	
PAS	disorder	and	34%	of	those	present	outside	working	hours.26
Overall,	 MDTs	 demonstrate	 ongoing	 improvements	 in	 patient	
safety	with	increasing	experience	and	reflective	changes	in	care	plans.	






Median units of packed red blood cells transfused 3.5–5.4	L
Large-	volume	blood	transfusions	(>10	L) 5%–40%
Injury to bladder 7%–48%
Injury to ureter 0–18%











Radiologic	expertise	for	diagnosis Ultrasound and/or MRI






management of pregnant women
Neonatal intensive care unit and neonatalogists To	manage	both	planned	late	preterm	delivery	and	unplanned	preterm	delivery
Adult intensive care unit and intensivists Surgical	and	medical	intensive	care	unit	for	postoperative	care	as	required
Massive transfusion capacity Access to blood products/bank, massive transfusion protocol, transfusion medicine 
specialists/blood	bank	pathologists
Additional	surgical	expertise	when	required:	urology,	





Cell saver and perfusionists If	available,	may	be	cost-	effective	depending	on	frequency	of	transfusion	of	
allogenic blood
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loss,	proportion	of	women	receiving	blood	transfusions,	proportions	





Despite	 the	 clear	 benefits	 of	 decreased	 maternal	 morbidity,	 no	
benefit	 or	 adverse	 effect	 on	 neonatal	 outcomes	 has	 been	 demon-
strated	with	MDT	care	for	PAS	disorders	in	CoE.11,15	Operative	times	
with	MDTs	may	 be	 significantly	 longer.	 Surgeries	 in	 a	 single	 center	
were	 260	±	68	minutes	with	 the	 team	 and	 181	±	57	minutes	 in	 the	




are not available in low- income and most middle- income countries.
2.2 | Timing of delivery






delivery.9–11,15,18,28,29	 The	 majority	 of	 cases	 of	 PAS	 disorders	 are	
now	associated	with	placenta	previa,13,14	and	thus	as	gestational	age	
increases	the	likelihood	of	major	prepartum	hemorrhage	increases.
Scheduled	 nonemergent	 deliveries	 result	 in	 a	 significant	 reduc-
tion	 in	 maternal	 morbidity	 due	 to	 PAS	 disorders.	 Complications	
related	to	blood	loss	are	lower	in	nonemergent	compared	with	emer-
gent deliveries.12,13,16	 This	 knowledge	 has	 led	 to	 the	 scheduling	 of	
surgical	 interventions	 with	 planned	 late	 preterm	 (35–36	weeks)	 or	
early	term	(37	weeks)	delivery	as	a	mechanism	to	avoid	the	need	for	
emergency	surgery.	An	MDT	care	plan	that	included	planned	delivery	
at	 34–35	weeks	 demonstrated	 a	 reduction	 in	 emergency	 deliveries	
from	23%	to	64%	with	no	adverse	effects	on	neonatal	outcomes.11




ing	 as	 reflected	 in	 quality-	adjusted	 life	years.30	There	 is	 no	 role	 for	
assessing	 fetal	 lung	maturity	with	amniocentesis	and	 little	benefit	 is	











who	may	 benefit	 the	most	 from	 a	 strategy	 of	 planned	 late	 preterm	
delivery	are	those	with	a	history	of	episodes	of	prepartum	hemorrhage,	
PPROM,	or	uterine	contractions.28,29	The	corollary	remains	that	women	












size (n) Study design Comparator Improvements with MDT care vs control





























of standardized MDT in 3 
tertiary	hospitals 

























There	 are	 some	 centers	 where,	 resources	 permitting,	 erythropoietin	
therapy	is	combined	with	concomitant	intravenous	iron	treatment.
2.4 | Minimizing unintended urologic injury
In	a	systematic	review	of	surgical	techniques	used	for	PAS	disorders,	
the	overall	rate	of	unintentional	urinary	tract	injury	at	peripartum	hys-
terectomy	was	 29%	 (83/285)—higher	 than	 rates	 for	 hysterectomies	
for	other	gynecologic	 indications.33	Seventy-	eight	percent	of	 injuries	




from	33%	 to	6%.33 At ureteric stent placement, cystoscopic assess-
ment	 can	also	evaluate	 for	evidence	of	bladder	 invasion	by	 the	pla-























of	 the	newly	 formed	vessels	might	complicate	 the	dissection	of	 the	






uation	of	 the	 amount	 of	 intraoperative	bleeding.	 Filling	 the	bladder	
before	the	surgical	procedure	helps	in	the	dissection	of	the	lower	seg-










sion	 (Box	 1).	 Historically,	 most	 patients	 with	 PAS	 disorders	 were	
managed	conservatively	with	general	anesthesia,	as	described	in	a	ret-









of	 conversion	 appear	 to	 occur	 in	 low-	income	 countries,	which	 also	
have	higher	rates	of	reported	blood	loss;	therefore,	general	anesthesia	
may	be	the	initial	method	of	choice	in	this	context.41
Several	 studies	 have	 reported	 decreased	 hemorrhage-	related	
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with	 regional	 compared	with	 general	 anesthesia.44,45	 Of	 these,	 one	
randomized	 clinical	 trial	 was	 specifically	 designed	 to	 study	 women	
with	placenta	previa	including	accreta,	and	while	it	demonstrated	that	
blood	transfusion	requirements	were	greater	in	the	general	anesthe-
sia	group,	 there	was	no	significant	difference	 in	 reported	blood	 loss	
overall.44	No	 significant	difference	 in	blood	 loss	or	volume	of	blood	
transfused	between	 regional	and	general	 anesthesia	was	 found	 in	a	
recent	retrospective	cohort	of	50	cases	of	placenta	accreta	managed	
by a single Canadian CoE.43




3.2 | Type of incisions for access
Avoiding	 the	 placenta	 at	 planned	 cesarean	 hysterectomy	 reduces	






of	 the	uterus	may	be	 adequate	 if	 the	upper	margin	of	 the	placenta	
does	not	rise	into	the	upper	segment	of	the	uterus	and	no	hysterec-
tomy	 is	planned.	However,	 it	may	not	provide	sufficient	exposure	 in	
cases	of	placenta	percreta.	 If	 the	placenta	 is	anterior	and	extending	
toward	the	level	of	the	umbilicus,	and/or	a	hysterectomy	is	planned,	






















Most recently, a large double- blind placebo- controlled trial 
recruited	over	20	000	patients	with	postpartum	hemorrhage	 to	 the	
WOMAN	 trial.47	 The	 study	 demonstrated	 that,	 compared	with	 pla-
cebo,	 tranexamic	 administration	 significantly	 reduced	 death	 due	 to	
massive	 obstetric	 hemorrhage	 without	 increasing	 rates	 of	 adverse	
events,	including	thromboembolism.
A	 recent	 meta-	analysis	 of	 nine	 trials	 involving	 2365	 patients	
confirmed	 these	 findings,	 demonstrating	 that	 the	 administration	 of	
tranexamic	acid	before	cesarean	delivery	 significantly	 reduces	 intra-	
and	postoperative	blood	loss	and	blood	transfusion	with	no	increase	
in	thromboembolic	events.48	After	this	analysis,	three	more	placebo-	
controlled	 trials	 have	 shown	 that	 tranexamic	 acid	 administration	
immediately	 before	 cesarean	 delivery	 significantly	 reduces	 reported	












interventional	 radiologists	 into	 the	 aorta,	 common	 iliac,	 internal	 iliac,	
or	uterine	arteries	under	fluoroscopic	guidance	and	are	inflated	when	
hemorrhage	is	encountered.	Many	authors	have	advocated	their	use,	
claiming	 a	 decrease	 in	 blood	 loss	 and	 transfusion	 requirements,	 and	
improved	visualization	on	the	surgical	field.52–68	However,	other	stud-
ies	 fail	 to	demonstrate	any	benefit	and	criticize	 their	use.69–73	These	
authors	 claim	 that	 occlusive	 balloons	 cannot	 prevent	 catastrophic	
bleeding	since	the	blood	supply	to	the	pelvis	is	maintained	by	the	devel-
opment	of	rich	collaterals	during	pregnancy.73,74	In	fact,	they	postulate	
that	 the	empiric	 inflation	of	 these	balloons	 in	a	 relatively	dry	setting	
may	 actually	 exacerbate	 bleeding	 from	 such	 collaterals.71–74	 Finally,	
reports	of	vessel	rupture	and	thromboembolic	catheter-	related	compli-
cations	have	called	into	question	these	balloons’	risk–benefit	ratio.75–81





3.3.3 | Internal Iliac artery ligation
Advantages	to	surgically	ligating	the	internal	iliac	arteries	are	similar	to	
those	for	balloon	occlusion	devices.	However,	with	the	proper	skillset,	
surgical	 internal	 iliac	 artery	 ligation	 has	 the	 added	 benefit	 of	 being	
available	in	low-	and	middle-	income	countries,	where	access	to	inter-
ventional	radiology	may	be	limited.
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Studies	 evaluating	 the	 safety	 and	 effectiveness	 of	 internal	 iliac	
artery	ligation	in	the	context	of	PAS	disorders	specifically	are	few.	In	a	











products	 including	 Jehovah’s	witnesses.83,84	Whilst	 cell	 salvage	 and	
retransfusion	are	viewed	as	relatively	expensive	and	 labor	 intensive,	
autologous cell salvage is now being adopted in many obstetric centers 
managing	PAS	disorders,	with	observational	studies	showing	improved	
outcomes	and	reduced	need	for	allogenic	blood	transfusion,	without	
an increase in adverse outcomes.84–86 Regarding cost analysis, a recent 


















In	 two	 additional	 retrospective	 cohorts,	 MDT	 care	 was	 associated	
with	 statistically	 lower	 rates	 of	 attempted	 placental	 removal	 and	 a	
reduction	in	blood	transfusion	rates,	large-	volume	blood	transfusion,	
and	estimated	blood	 loss	 for	PAS	disorders.17,23	However,	 in	 select	
patients,	intraoperative	inspection	of	the	uterus	at	cesarean	delivery	
may	allow	a	 trial	of	placental	 separation	 in	 suspected	cases	of	PAS	
disorders	without	increasing	morbidity.89	This	study	had	a	high	rate	of	
TABLE  4 Novel	techniques	for	cesarean	hysterectomy	in	patients	with	placenta	accreta	spectrum	(PAS)	disorders.




























Belfort et al.90; 
USA	(n=3)
Linear	cutting	
staple device for 
hysterotomy
Midline	abdominal	incision,	uterus	exteriorized,	and	site	of	hysterotomy	identified	high	on	upper	
uterine segment of fundus









Use of vessel- sealing 
devices	for	Peripartum	
Hysterectomy
Vessel sealing device used to facilitate surgery







This	 is	 consistent	 with	 evidence	 from	 retrospective	 cohort	 studies,	
demonstrating	fewer	attempts	at	placental	removal	by	MDTs	in	CoE.
Overall,	in	the	setting	of	planned	immediate	hysterectomy	for	PAS	
disorders,	 no	 attempt	 at	 manual	 separation	 should	 be	 undertaken	
because	 leaving	 the	 placenta	 in	 situ	 is	 associated	with	 lower	 blood	




disorders, unless placental removal is imminent35 or complete placen-
tal	separation	occurs	thus	ruling	out	PAS	disorders.
4  | TECHNIQUES FOR HYSTERECTOMY
4.1 | Total versus subtotal hysterectomy
Total	 hysterectomy	 is	 the	 recommended	 surgical	 method	 for	
	emergent	peripartum	hysterectomy	owing	 to	 the	potential	 risk	of	
malignancy	developing	 in	 the	cervical	 stump,	 the	need	 for	 regular	
cervical	 cytology,	 and	 other	 associated	 problems	 such	 as	 bleed-
ing	 or	 discharge.	 Proponents	 of	 subtotal	 hysterectomy	 report	
decreased	 blood	 loss,	 blood	 transfusions,	 perioperative	 complica-
tions,	and	shorter	operating	time.	However,	subtotal	hysterectomy	
may	not	be	effective	in	the	management	of	placenta	increta	or	per-
creta	 if	 cervical	 involvement	 is	 present	 and	 a	 total	 hysterectomy	
should	be	the	preferred	option	in	these	cases.	In	addition,	subtotal	
hysterectomy	 has	 not	 been	 shown	 to	 provide	 protection	 against	
	urinary	tract	 injury	compared	with	total	hysterectomy	in	surgeries	
for	PAS	disorders.33




4.2 | Other novel surgical techniques
Numerous	 centers	 have	 modified	 their	 surgical	 techniques	 in	 an	
attempt	 to	 minimize	 hemorrhage	 and/or	 to	 reduce	 unintentional	
injury	 to	 the	 urinary	 tract.11,36,90,91	 These	 techniques	 involve	 early	






surrounding	 structures	would	 render	 immediate	 cesarean	 hysterec-
tomy	extremely	 difficult.	Allowing	 some	 resorption	of	 the	placenta,	
decrease	 in	vascularity	and	 involution	of	the	uterus	 is	postulated	to	
facilitate	later	surgery.	However,	there	is	an	associated	risk	of	coagu-
lopathy,	hemorrhage,	 and	 sepsis	during	 the	 interim	period.	Patients	
must	be	compliant	with	follow-	up	and	resources	to	manage	patients	
urgently	if	complications	arise	should	be	available	24	hours	a	day.
Delayed	 hysterectomies	 are	 performed	 between	 3	 and	 12	weeks	
postpartum15,92,93 and many cases involve postdelivery uterine artery 











While	 traditionally	 these	 second	 surgeries	 involve	 a	 laparotomy,	
minimally	 invasive	 surgical	 approaches	 including	 robotics	have	been	
reported.92,94–96	This	approach	requires	advanced	skills	but	may	have	
enhanced	visualization	compared	with	laparotomy,	along	with	shorter	
recovery,	 although	 surgical	 times	 are	 quite	 prolonged	 (up	 to	 286–
330	minutes).92–96	 These	 techniques	 require	 care	 in	 CoE	with	 both	
advanced	 surgical	 programs	 and	 the	 capacity	 to	 manage	 emergent	
massive	obstetric	hemorrhage.
5  | RECOMMENDATIONS
Recommendations	 for	 the	 surgical	nonconservative	management	of	
PAS	disorders	are	given	in	Table	5.
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